6576 Stock Overview Operates as biopharmaceutical company in the United States, China, and Europe. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Foresee Pharmaceuticals Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Foresee Pharmaceuticals Historical stock prices Current Share Price NT$75.90 52 Week High NT$107.50 52 Week Low NT$68.40 Beta 1.2 1 Month Change -4.41% 3 Month Change -7.10% 1 Year Change -20.94% 3 Year Change -36.75% 5 Year Change 22.03% Change since IPO -31.31%
Recent News & Updates
Price target decreased by 12% to NT$127 Dec 13
New minor risk - Shareholder dilution Dec 11 Foresee Pharmaceuticals Co., Ltd. has completed a Follow-on Equity Offering in the amount of TWD 1.368 billion. Dec 04
Foresee Pharmaceuticals Receives the Second Positive Recommendation from DSMB to Continue the Casppian Study Nov 15
Foresee Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Nov 13, 2024 Nov 06
Foresee Pharmaceuticals Co., Ltd. Announces Submission of the NDA to the U.S. FDA for the 3-month Version of CAMCEVI for the Treatment of Advanced Prostate Cancer Oct 30 See more updates
Price target decreased by 12% to NT$127 Dec 13
New minor risk - Shareholder dilution Dec 11 Foresee Pharmaceuticals Co., Ltd. has completed a Follow-on Equity Offering in the amount of TWD 1.368 billion. Dec 04
Foresee Pharmaceuticals Receives the Second Positive Recommendation from DSMB to Continue the Casppian Study Nov 15
Foresee Pharmaceuticals Co., Ltd. to Report Q3, 2024 Results on Nov 13, 2024 Nov 06
Foresee Pharmaceuticals Co., Ltd. Announces Submission of the NDA to the U.S. FDA for the 3-month Version of CAMCEVI for the Treatment of Advanced Prostate Cancer Oct 30
Foresee Pharmaceuticals Co., Ltd. Announces on Behalf of Subsidiary, Foresee Pharmaceuticals Australia Pty Ltd, the Preliminary Results from the Linvemastat (Fp-020) Phase 1 Trial Oct 21
Second quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 17
Foresee Pharmaceuticals Co., Ltd. Announces Several New Developments Related to its SIF Long-Acting Injectable (LAI) Technologies - Solidifying its Position as a Leader in Complex Long-Acting Injectability Products Aug 10
Foresee Pharmaceuticals Co., Ltd. to Report Q2, 2024 Results on Aug 14, 2024 Aug 07
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind May 19
Foresee Pharmaceuticals Announces First Subject Dosed in Its First-In-Human Clinical Trial of FP-020 Apr 30
Foresee Pharmaceuticals Co., Ltd. to Report Q1, 2024 Results on May 03, 2024 Apr 28
Foresee Pharmaceuticals Receives Positive Recommendation from Data and Safety Monitoring Board to Continue the Casppian Study Apr 02
Full year 2023 earnings: EPS misses analyst expectations Mar 31 Foresee Pharmaceuticals Co., Ltd. has filed a Follow-on Equity Offering.
Consensus revenue estimates fall by 38% Feb 20
Foresee Pharmaceuticals Co., Ltd. Announces Last Patient Enrolled in the China Registration Clinical Trial of Leuprolide Injectable Emulsion in Prostate Cancer Has Completed Treatment Nov 30
Foresee Pharmaceuticals Co., Ltd. Submits Phase 3 IND (Investigational New Drug) Application to China NMPA Oct 17
Foresee Pharmaceuticals Announces First Patient Dosed in the Casppian, Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion, 42 mg for the Treatment of Central Precocious Puberty Patients Oct 14
Foresee Pharmaceuticals to Present Phase 1/2 Fanconi Anemia Clinical Study Design for its ALDH2 Activator FP-045 at the Fanconi Anemia Research Fund 2023 Scientific Symposium Oct 01
New minor risk - Shareholder dilution Sep 02
Foresee Pharmaceuticals Announces FDA Orange Book Listing of New U.S. Patent for Camcevi®, Extending Patent Protection to 2039 Aug 30
New minor risk - Revenue size Aug 17
Second quarter 2023 earnings: Revenues miss analyst expectations Aug 17
Forecast to breakeven in 2024 Jul 13
Price target decreased by 12% to NT$122 Jul 12
No longer forecast to breakeven Jun 30 Foresee Pharmaceuticals Co., Ltd. Announces Appointment of Ben Liu as Independent Director
Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Feb 26
Foresee Pharmaceuticals Co., Ltd. Receives Approval from China NMPA for the Application of Phase 3 IND for FP-001 42 mg in Patients with Central Precocious Puberty Jan 19
Foresee Pharmaceuticals Co., Ltd. Receives Approval from Taiwan FDA for the Application of Phase 3 IND for FP-001 42 Mgin Patients with Central Precocious Puberty Jan 03
Foresee Pharmaceuticals Co., Ltd. Announces the Submission of A Phase 3 Clinical Trial Application for FP-001 42 Mg in Patients with Central Precocious Puberty to EMA Dec 24
Less than half of directors are independent Nov 16
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Nov 13
Foresee Pharmaceuticals Co., Ltd. Announces Phase 3 Clinical Trial Application for Fp-00142 Mg in Patients with Central Precocious Puberty Has Been Accepted by China NMPA for Substantial Review Nov 03
Consensus revenue estimates fall by 32% Sep 21
Foresee Pharmaceuticals Co., Ltd. Proceeds with FP-001 42 Mg Phase 3 Clinical Trial in Patients with Central Precocious Puberty Aug 23
Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Aug 14
Foresee Pharmaceuticals Co., Ltd. Submits IND for FP-045 in Patientswith Fanconi Anemia by TRPharm to the Ministry of Health of Turkey Aug 12
Foresee Announces Phase 2 Results of FP-025 Inpatients with Covid-19 Associated ARDS Aug 05
Forecast to breakeven in 2024 Jun 17
Foresee Pharmaceuticals Announces European Commission Approval of CAMCEVI® for the Treatment of Advanced Prostate Cancer Jun 01
First quarter 2022 earnings released: NT$1.04 loss per share (vs NT$1.36 loss in 1Q 2021) May 16
Foresee Pharmaceuticals Co., Ltd. Approves Appointment of Max Chan as Corporate Governance Officer May 14
Israel Accepts for Substantial Review of Marketing Authorization Application for CAMCEVI 42 mg of Foresee Pharmaceuticals Co., Ltd May 13
Price target increased to NT$130 Apr 27
Less than half of directors are independent Apr 27
Accord BioPharma in Partnership with Foresee Pharmaceuticals Co., Ltd., the U.S. Launch of CAMCEVI (Leuprolide) 42Mg Injection Emulsion for the Treatment of Advanced Prostate Cancer in Adults Apr 06
Full year 2021 earnings: EPS exceeds analyst expectations Mar 28
No longer forecast to breakeven Mar 28
Price target increased to NT$130 Feb 09
Consensus forecasts updated Jan 06
Foresee Pharmaceuticals Co., Ltd. Announces Registration Clinical Trial Application for CAMCEVI42 Mg Accepted by China NMPA for Substantial Review Jan 03
Foresee Pharmaceuticals Co., Ltd. Announces Positive Recommendation from Second IDMC Review Meeting to Continue FP-025 Covid-19/ARDS Phase 2/3 Study Nov 25
Tolmar Files Complaint Against Foresee Pharmaceuticals Co., Ltd. for Patent Infringement Aug 25
Foresee Announces Positive Recommendation from IDMCPhase 2 Safety Review Meeting to Continue FP-02 Covid-19/ARDS Phase 2/3 Study Without Change Jul 07
Price target increased to NT$125 Jun 22
Foresee Pharmaceuticals Co., Ltd. Announces FDA Approval of CAMCEVI 42 mg for the Treatment of Advanced Prostate Cancer May 27
Price target decreased to NT$112 May 25
First quarter 2021 earnings released: NT$1.36 loss per share (vs NT$1.10 loss in 1Q 2020) May 15
Senior Director & Head of QA has left the company Apr 28
We Might See A Profit From Foresee Pharmaceuticals Co., Ltd. (GTSM:6576) Soon Mar 24
New 90-day high: NT$107 Mar 06
Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States Mar 05
Foresee Received Notification from US FDA That Itmay Proceed with the FP-025 Phase 2/3 Clinical Trials Inpatients with COVID-19 Associated ARDS Jan 26
Price target lowered to NT$123 Jan 08
Foresee Pharmaceuticals Co., Ltd. announced that it has received TWD 90 million in funding Dec 26
Foresee Pharmaceuticals Co., Ltd. has completed a Follow-on Equity Offering in the amount of TWD 1.32 billion. Dec 25
Investors Who Bought Foresee Pharmaceuticals (GTSM:6576) Shares A Year Ago Are Now Up 41% Dec 22
Foresee Pharmaceuticals Enters Into Exclusive License Agreement with GenScience Pharmaceuticals for the Commercialization of Camcevi(TM) in China Nov 18
New 90-day high: NT$102 Nov 17
Earnings miss expectations Nov 14
Foresee Pharmaceuticals Co., Ltd. Announces New Drug Application for FP-001 LMIS 50mg Accepted for Review by the U.S. Food and Drug Administration Oct 10
Analysts lower revenue estimates to NT$143.0m Sep 29
First half earnings released Aug 14 Shareholder Returns 6576 TW Pharmaceuticals TW Market 7D 3.0% -0.01% -2.1% 1Y -20.9% -2.7% 25.6%
See full shareholder returns
Return vs Market: 6576 underperformed the TW Market which returned 25.6% over the past year.
Price Volatility Is 6576's price volatile compared to industry and market? 6576 volatility 6576 Average Weekly Movement 3.0% Pharmaceuticals Industry Average Movement 3.7% Market Average Movement 4.4% 10% most volatile stocks in TW Market 7.8% 10% least volatile stocks in TW Market 2.1%
Stable Share Price: 6576 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6576's weekly volatility (3%) has been stable over the past year.
About the Company Foresee Pharmaceuticals Co., Ltd. operates as biopharmaceutical company in the United States, China, and Europe. The company’s stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases.
Show more Foresee Pharmaceuticals Co., Ltd. Fundamentals Summary How do Foresee Pharmaceuticals's earnings and revenue compare to its market cap? 6576 fundamental statistics Market cap NT$11.75b Earnings (TTM ) -NT$930.72m Revenue (TTM ) NT$346.56m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 6576 income statement (TTM ) Revenue NT$346.56m Cost of Revenue NT$192.41m Gross Profit NT$154.16m Other Expenses NT$1.08b Earnings -NT$930.72m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -6.01 Gross Margin 44.48% Net Profit Margin -268.56% Debt/Equity Ratio 49.6%
How did 6576 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/21 04:57 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Foresee Pharmaceuticals Co., Ltd. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution null null KGI Securities Co. Ltd. Hsuan Chen KGI Securities Co. Ltd. Hengyu Fu Masterlink Securities Corp.
Show 2 more analysts 
